Page 2 - Biocon Ltd News

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has received an approval from Health Canada for chronic autoimmune conditions treatment medications Yesintek and Yesintek IV. The notice of compliance (NOC) granted by Health Canada is for Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for injection, solution for intravenous infusion), Biocon Ltd said in a regulatory filing. Yesintek and Yesintek IV are biosimilars to Stelara (ustekinumab injection) and Stelara IV (ustekinumab for injection, solution for intravenous infusion), respectively. The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October, the company said. "Health Canada's approval of Yesintek marks a significant milestone in our mission to expand global access to high-quality biosimilars," Biocon Biologics CEO & Managing Director Shreehas Tambe said. He further said, "Building on our successful US launch, this approval strengthens our presence in ...

Here's why Biocon shares were trading higher on the bourses on October 20

Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon, announced the expansion of its strategic collaboration with Civica, Inc. (Civica)

Biocon Biologics expands Civica tie-up to launch pvt-label insulin in US

The move aims to increase the availability of affordable insulin for the country's 38.4 million diabetes patient

Stocks to watch, Oct 17: RIL, Infosys, Jio Fin, Wipro, Havells, Canara HSBC

Around 7:20 AM, GIFT Nifty futures were down 41.6 points at 25,614.5, indicating a negative start.

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin

The USFDA's tentative approval means Biocon Pharma's Rifaximin 550 mg meets regulatory requirements but cannot be marketed in the US yet due to patents or exclusivity on the original drug

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Biocon share price rises 3% as arm gets USFDA nod for two drugs; details

By 10:35 AM, Biocon share price was trading 2.84 per cent higher at ₹364.45 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 83,004.53 levels.

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars

Biocon Biologics gets USFDA approval for Bosaya and Aukelso, denosumab biosimilars of Prolia and Xgeva, with provisional interchangeability status to widen patient access

Stocks to watch today, Sep 11: Bajaj Finserv, DRL, Mazagon, Jupiter Wagons

Stocks to watch on Thursday, September 11: Keystone Realtors, RVNL, Deepak Fertilisers, Torrent Pharma and Adani Ports are among top stocks to track today.

Biocon shares gain 2% after USFDA inspection at Bengaluru facility; details

The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses

Biocon shares slip 3% as Q1 results miss estimates; should you sell?

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

Confident about Biocon's response to US tariffs: Kiran Mazumdar-Shaw

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon Chairperson

Biopharma stock under ₹500 plunges 4%; what should investors do?

The biopharma company's revenue from operations for the quarter ended June 30, 2025, surged 15 per cent year-on-year (Y-o-Y) to ₹3,942 crore, as compared to ₹3,433 crore reported in Q1FY25.

Sensex sinks 600 pts, Nifty near 24,400 amid Trump's tough trade talk

Broader markets witnessed a steeper decline. The Nifty Midcap 100 was trading 0.86 per cent lower, quoting 56,449 levels. Nifty Smallcap, meanwhile, was trading at 17,594, down by 0.56 per cent.

Biocon Q1 results: Net profit down 95%, revenue rises 15% to ₹4,022 cr

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Biocon Biologics appoints Deepali Naair Global Head, Brand & Corp Comm

Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head Brand & Corporate Communications, effective immediately. Deepali will lead the global brand and corporate communications function, responsible for defining and executing an integrated strategy that spans brand positioning, digital presence, regulatory and statutory communications, financial and corporate reporting, media relations, and employer branding, Biocon Biologics, a subsidiary of Biocon Ltd, said in a statement. With over three decades of experience across India, ASEAN, and Australia, Naair brings deep expertise in brand building, marketing, and corporate reputation. In her most recent role as Group Chief Marketing Officer at CKA Birla Group, she was instrumental in shaping the Group's corporate identity, launching new brands, and driving strategic transformations, Biocon Biologics stated. Naair will join the company's Executive Leadership Team (ELT) and report directly to Shreehas ...